- ¥158bn
- ¥108bn
- ¥97bn
Table: Kissei Pharm - 9-MTH group results
Marketing Authorization For Oral Spleen Tyrosine Kinase Inhibitor Tavalisse In South Korea
Sub-Licensing Agreement For Oral Spleen Tyrosine Kinase Inhibitor Tavalisse With Tai Tien Pharmaceuticals In Taiwan
Launch Of Yselty (Generic Name Linzagolix) For Uterine Fibroid Treatment In Europe
Licensing Agreement For "Olutasidenib", An Acute Myeloid Leukemia Drug
Table: Kissei Pharm -Q1 group results
Table: Kissei Pharm -2023/24 parent results
Table: Kissei Pharm -2023/24 group results
Announces Result Of Share Buyback For January
Table: Kissei Pharm - 9-MTH group results
Brief: Kissei Pharmaceutical Co Ltd Bought Back 80,600 Own Shares Worth 251 Million Yen In December
Brief: Kissei Pharmaceutical Co Ltd Announces Result Of Share Buyback For November
Bought Back 1,165,300 Own Shares Worth 3.68 Billion Yen On Tuesday Before Market Open
To Buy Back Up To 2.62% Of Shares Worth 3.792 Billion Yen On Tuesday Via Tostnet-3
Table: Kissei Pharm - 6-MTH group results
2023 6-month group forecast
Announces Result Of Share Buyback For July
Table: Kissei Pharm -Q1 group results
Brief: Kissei Pharmaceutical Co Ltd Announces Withdrawal Of Application For Marketing Approval For Rovatirelin(KPS-0373) For Treatment Of Spinocerebellar Degeneration In Japan